FDA Approves Kisunla (donanemab-azbt) for the Treatment of Early Symptomatic Alzheimer's Disease
FDA approves Kisunla (donanemab-azbt) for early symptomatic Alzheimer's disease, targeting amyloid plaques. Kisunla, a once-monthly IV infusion, shows potential to stop therapy upon plaque removal, reducing costs and infusions. Clinical trials demonstrate significant slowing of clinical decline and amyloid plaque reduction, though risks include amyloid-related imaging abnormalities (ARIA) and infusion-related reactions.
Highlighted Terms
Related News
FDA approves Kisunla (donanemab-azbt) for early symptomatic Alzheimer's disease, targeting amyloid plaques. Kisunla, a once-monthly IV infusion, shows potential to stop therapy upon plaque removal, reducing costs and infusions. Clinical trials demonstrate significant slowing of clinical decline and amyloid plaque reduction, though risks include amyloid-related imaging abnormalities (ARIA) and infusion-related reactions.